SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to community discussion around earnings and a subsequent price dip, with debates focusing on valuation and the influence of Michael Burry's short position. Some are optimistic about a rebound, citing AI hype and strong fundamentals, while others express concern about overvaluation and potential downside. CEO Alex Karp's remarks about shorts on CNBC are also fueling discussion.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to recent earnings and trial data sparking debate, with discussion focused on the impact of a failed confirmatory trial on existing PMO therapies and the future of Elevidys. The community is weighing the potential for FDA action, the significance of 'missed' data, and whether the stock is now undervalued or facing further decline. Some traders see this as an opportunity for a short squeeze.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid discussions around its pursuit of Metsera and competition with Novo Nordisk in the obesity drug market, as well as an upcoming earnings report and dividend payout. The community is focused on the potential impact of the Metsera acquisition and whether Pfizer can maintain its competitive edge. Some traders are eyeing potential breakouts while others express frustration with the stock's historical performance.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending after positive numbers sparked buyout speculation within the community, despite a generally negative market day. Community members are also closely following developments around patent extensions and potential new indications for AUR200. Some investors express frustration with management, while others remain optimistic about the company's long-term potential.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz is trending as community members discuss a potential short squeeze amid high short interest and recent earnings. The company's turnaround efforts, including cost-cutting and diversification, are also key talking points. Bullish sentiment is building, especially with chatter around the Amazon partnership.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the meme-based crypto, emphasizing retail unity and a return to OG memecoin values. Community members express strong conviction and a belief in building a lasting movement, viewing $RAGE as more than just hype. The focus is on a cult-like community and the power of memes in the crypto space.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

UBER is trending as investors digest mixed signals post-earnings, balancing strong performance metrics with concerns about guidance and broader market conditions. Community discussions revolve around whether the dip represents a buying opportunity, with some highlighting the potential for long-term growth driven by autonomous vehicle initiatives. Several analysts have reiterated Buy ratings, noting robust growth, while others observe that the stock price has been disconnected from fundamentals.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the price experiences volatility, sparking debates about whether this is a healthy pullback or the start of a deeper correction. Community discussions revolve around key support levels, potential bottom fishing opportunities, and whether institutions are driving the price action. Some traders express concern about overleveraged positions and the possibility of a crypto winter.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as it engages in a bidding war with Pfizer to acquire Metsera, a company with promising obesity drug assets; the community debates whether this acquisition strategy is the right move. Some believe Novo is strategically blocking a competitor, while others suggest focusing on share buybacks, particularly amidst concerns about market share competition with Eli Lilly. Recent messages also highlight anticipation for upcoming earnings and potential FDA approval for Novo's oral Wegovy.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as community members highlight its strong ties to the Bitcoin network and its fair distribution via airdrop. Discussion centers on $DOG being the premier meme coin on Bitcoin and the growing $DOG army. The connection between $DOG and $CBLO, a public company accumulating $DOG, is also a key talking point.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.</li><li>Subscriber count grew 21% to almost 2.5 million, with monthly online revenue per subscriber up 19% to $80.</li><li>On Stocktwits, retail sentiment was ‘extremely bullish,’ with users predicting the stock could climb toward $50 once Novo Nordisk partnership talks conclude.</li></ul>Shares of Hims &amp; Hers Health rose about 5% in after-hours trading on Monday after the company reported another quarter of strong growth and said it’s in talks with Novo Nordisk to bring&nbsp;weight-loss drug Wegovy to its platform.<h2 class="st-heading-2">Revenue And Subscriber Growth Remain Strong</h2>Revenue rose 49% from a year earlier to $599 million as strength continued across the company’s weight-loss and wellness businesses. Net income was $15.8 million, versus $75.6 million a year ago, which had reflected a one-time tax benefit. Adjusted EBITDA increased 53% to $78.4 million.Hims &amp; Hers now has nearly 2.5 million subscribers, up 21% from a year earlier, and monthly revenue per subscriber has also risen 19% to $80. Cash from operations soared to $149 million, while free cash flow for the quarter remained stable at $79 million.Gross margin fell to 74%, from 79% a year earlier, mainly due to changes in shipping cadence and higher production costs related to Hims &amp; Hers’ growing weight-loss portfolio.<h2 class="st-heading-2">Talks With Novo Nordisk</h2>The company said it’s in active talks with Novo Nordisk to make Wegovy injections and an eventual oral formulation available on its platform once they have prescribing approval. No agreement has been reached, and the company said that a deal is not guaranteed.The company said during the earnings call that it expects to bring in over $725 million in weight-loss revenue this year, and that it’s spending money to build new sterile compounding and fulfillment centers to keep up with the surge in demand.<h2 class="st-heading-2">Outlook For 2025</h2>Hims &amp; Hers narrowed its 2025 revenue forecast to a range of $2.335 billion to $2.355 billion, slightly above its previous estimate of $2.3 billion to $2.4 billion. It now expects adjusted EBITDA between $307 million and $317 million, compared with the earlier range of $295 million to $335 million.For the fourth quarter, the company expects revenue of $605 million to $625 million and adjusted EBITDA of $55 million to $65 million. The company said near-term margins will be affected by ongoing investments in its compounding operations and by price adjustments to GLP-1 drugs, though it expects conditions to improve next year as volumes continue to rise.<h2 class="st-heading-2">Stocktwits Traders Bet On Further Gains</h2>On Stocktwits, retail sentiment for Hims was ‘extremely bullish’ amid a 1,734% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/135;" src="https://news.stocktwits-cdn.com/hims_ss_jpg_d349536f51.webp" alt="hims ss.jpg" width="968" height="135"><figcaption>HIMS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed the stock as a solid buy for the next move higher, expecting it to stay above the $30 range.&nbsp;<stembedurl>https://stocktwits.com/Lucy888/message/634788120</stembedurl>Another predicted that shares could climb toward $50 following the company’s strong results and new initiatives. Meanwhile, a third user said the stock could rally sharply once its ongoing discussions with Novo Nordisk are concluded.<stembedurl>https://stocktwits.com/bestest1/message/634776299</stembedurl><stembedurl>https://stocktwits.com/Maximusprofit/message/634778175</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health’s stock</a> has risen 84% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a HIMS logo is displayed on a smartphone. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Equity

Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 0.00% and +2.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

Hims & Hers Health, Inc. (Hims & Hers or the Company, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a...

<ul class="summary-bullets"><li>Hims &amp; Hers Health announced last week that it was providing compounded GLP-1 microdosing treatment plans, giving flexible options to tailor care for those who can benefit.</li><li>The company is expected to post third-quarter revenue of $579.9 million and earnings per share of $0.10, according to data from Fiscal AI.</li><li>In late October, KeyBanc initiated coverage of Hims &amp; Hers Health with a ‘Sector Weight’ rating, according to TheFly.</li></ul>Hims &amp; Hers Health (HIMS) is set to report third-quarter results after the markets close on Monday, with investors focusing on the company’s ramp-up of GLP-1 drugs and expansion into more drugs.The company is expected to post third-quarter revenue of $579.9 million and earnings per share of $0.10, according to data from Fiscal AI.Retail sentiment on the Hims &amp; Hers remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to data from Stocktwits.<h2 class="st-heading-2">GLP-1 Drugs Expansion</h2>The company last week announced that it was providing compounded GLP-1 microdosing treatment plans, giving flexible options to tailor care for those who can benefit.GLP-1 medications have seen a surge in demand in the U.S. after these drugs, which were developed to treat Type 2 diabetes, have also shown signs to help with weight loss.Last year, the company announced the addition of GLP-1 injections to its comprehensive weight loss portfolio. It had then said that it offers access to GLP-1 injections in addition to weight management oral medication kits.<h2 class="st-heading-2">Analyst Take</h2>In late October, KeyBanc initiated coverage of Hims &amp; Hers stock with a ‘Sector Weight’ rating, according to TheFly. The firm stated it was "intrigued" by the company's international ramp and expansion into more treatments, but believes it may lead to "more muted" margin expansion in 2026.&nbsp;A bullish user on Stocktwits noted that they were expecting a positive free cash flow in the third quarter from the ongoing investments.<a href="https://stocktwits.com/Wolfeyetrader7/message/634703970">https://stocktwits.com/Wolfeyetrader7/message/634703970</a>Shares of Hims &amp; Hers Health have gained nearly 117% in the last 12&nbsp; months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/openai-partners-with-aws-in-38-b-cloud-pact-using-nvidia-gpus/cL2N46zR3zZ">OpenAI Partners With AWS In $38B Cloud Pact To Scale AI Workloads Using Nvidia GPUs</a>

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Q3 Preview: GLP-1 Drug Expansion Draws Investor Focus

The company is expected to post third-quarter revenue of $579.9 million and earnings per share of $0.10, according to data from Fiscal AI.

OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Hims & Hers Scales AI-Driven Personalized Health and Wellness

HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc. LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc...

Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?

Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.

Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for

Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts

Hims & Hers Health, Inc. (HIMS) reached $47.12 at the closing of the latest trading day, reflecting a -2.3% change compared to its last close.

$HIMS Q3 &#39;25 Earnings Results &amp; Recap 
 
Hims &amp; Hers Health Inc reported Q3 &#39;25 revenue of nearly $600 million, beating estimates of $580.24M, and Q4 revenue is expected to be between $605 to $625 million, representing a year over year growth rate of between 26 and 30%.

Stocktwits

Hims & Hers Health Inc

 Q3 '25 Earnings Results & Recap 
 
Hims & Hers Health Inc reported Q3 '25 revenue of nearly $600 million, beating estimates of $580.24M, and Q4 revenue is expected to be between $605 to $625 million, representing a year over year growth rate of between 26 and 30%.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMSHims & Hers Health Inc